These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30219580)

  • 41. An Open Label Exploratory Clinical Trial Evaluating Safety and Tolerability of Once-Weekly Prednisone in Becker and Limb-Girdle Muscular Dystrophy.
    Zelikovich AS; Joslin BC; Casey P; McNally EM; Ajroud-Driss S
    J Neuromuscul Dis; 2022; 9(2):275-287. PubMed ID: 35124660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and disease monitoring biomarkers in Duchenne muscular dystrophy: results from a Phase II trial.
    Wagner KR; Guglieri M; Ramaiah SK; Charnas L; Marraffino S; Binks M; Vaidya VS; Palmer J; Goldstein R; Muntoni F
    Biomark Med; 2021 Oct; 15(15):1389-1396. PubMed ID: 34533053
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of glutamine on glucose metabolism in children with Duchenne muscular dystrophy.
    Letellier G; Mok E; Alberti C; De Luca A; Gottrand F; Cuisset JM; Denjean A; Darmaun D; Hankard R
    Clin Nutr; 2013 Jun; 32(3):386-90. PubMed ID: 23021433
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents.
    Herbelet S; Rodenbach A; Paepe B; De Bleecker JL
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605223
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence of muscle loss delay and improvement of hyperinsulinemia and insulin resistance in Duchenne muscular dystrophy supplemented with omega-3 fatty acids: A randomized study.
    Rodríguez-Cruz M; Atilano-Miguel S; Barbosa-Cortés L; Bernabé-García M; Almeida-Becerril T; Cárdenas-Conejo A; Del Rocío Cruz-Guzmán O; Maldonado-Hernández J
    Clin Nutr; 2019 Oct; 38(5):2087-2097. PubMed ID: 30420291
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy.
    Wagner KR; Abdel-Hamid HZ; Mah JK; Campbell C; Guglieri M; Muntoni F; Takeshima Y; McDonald CM; Kostera-Pruszczyk A; Karachunski P; Butterfield RJ; Mercuri E; Fiorillo C; Bertini ES; Tian C; Statland J; Sadosky AB; Purohit VS; Sherlock SP; Palmer JP; Binks M; Charnas L; Marraffino S; Wong BL
    Neuromuscul Disord; 2020 Jun; 30(6):492-502. PubMed ID: 32522498
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
    Campbell C; McMillan HJ; Mah JK; Tarnopolsky M; Selby K; McClure T; Wilson DM; Sherman ML; Escolar D; Attie KM
    Muscle Nerve; 2017 Apr; 55(4):458-464. PubMed ID: 27462804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy.
    Kinali M; Mercuri E; Main M; Muntoni F; Dubowitz V
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S169-74. PubMed ID: 12206813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial.
    Buyse GM; Voit T; Schara U; Straathof CSM; D'Angelo MG; Bernert G; Cuisset JM; Finkel RS; Goemans N; McDonald CM; Rummey C; Meier T;
    Lancet; 2015 May; 385(9979):1748-1757. PubMed ID: 25907158
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial.
    Mok E; Letellier G; Cuisset JM; Denjean A; Gottrand F; Alberti C; Hankard R
    PLoS One; 2009; 4(5):e5448. PubMed ID: 19421321
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced Diet.
    Muntoni F; Tejura B; Spinty S; Roper H; Hughes I; Layton G; Davies KE; Harriman S; Tinsley J
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):922-933. PubMed ID: 30650257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.
    King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT
    Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Daily prednisone treatment in Duchenne muscular dystrophy in southwest China.
    Hu J; Ye Y; Kong M; Hong S; Cheng L; Wang Q; Qin J; Zou L; Jiang L
    Muscle Nerve; 2015 Dec; 52(6):1001-7. PubMed ID: 25809413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
    Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
    PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Duchenne muscular dystrophy: an historical treatment review.
    Werneck LC; Lorenzoni PJ; Ducci RD; Fustes OH; Kay CSK; Scola RH
    Arq Neuropsiquiatr; 2019 Sep; 77(8):579-589. PubMed ID: 31508685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy.
    de Carvalho SC; Matsumura CY; Santo Neto H; Marques MJ
    Cytokine; 2018 Feb; 102():55-61. PubMed ID: 29276972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy.
    Hathout Y; Liang C; Ogundele M; Xu G; Tawalbeh SM; Dang UJ; Hoffman EP; Gordish-Dressman H; Conklin LS; van den Anker JN; Clemens PR; Mah JK; Henricson E; McDonald C
    Sci Rep; 2019 Aug; 9(1):12167. PubMed ID: 31434957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.